LOGIN  |  REGISTER
Viking Therapeutics
Cue Biopharma

Owens & Minor to Present at Upcoming Investor Conferences

December 02, 2024 | Last Trade: US$3.97 0.99 -19.96

RICHMOND, Va. / Dec 02, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), announced today that members of its management team are scheduled to participate in two upcoming investor conferences.

Citi 2024 Global Healthcare Conference

On Wednesday, December 4, 2024, Owens & Minor is scheduled to participate in a fireside chat at 8:45 a.m. ET and host individual investor meetings at the conference in Miami, Florida.

Bank of America Home Care Conference

On Monday, December 9, 2024, Owens & Minor is scheduled to participate in a fireside chat at 12:00 p.m. ET and host individual investor meetings at the virtual conference.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page